DKK1 and DPP4

Data Source:
BioGRID (two hybrid)

		DKK1	DPP4
Description		dickkopf WNT signaling pathway inhibitor 1	dipeptidyl peptidase 4
Image
GO Annotations	Cellular Component	Extracellular Region Extracellular Space Plasma Membrane Early Endosome Membrane	Extracellular Region Lysosomal Membrane Plasma Membrane Focal Adhesion Cell Surface Membrane Integral Component Of Membrane Apical Plasma Membrane Lamellipodium Endocytic Vesicle Lamellipodium Membrane Membrane Raft Intercellular Canaliculus Extracellular Exosome
	Molecular Function	Protein Binding Growth Factor Activity Co-receptor Binding Receptor Antagonist Activity Low-density Lipoprotein Particle Receptor Binding	Virus Receptor Activity Protease Binding Aminopeptidase Activity Serine-type Endopeptidase Activity Signaling Receptor Binding Protein Binding Serine-type Peptidase Activity Dipeptidyl-peptidase Activity Identical Protein Binding Protein Homodimerization Activity Chemorepellent Activity
	Biological Process	Negative Regulation Of Transcription By RNA Polymerase II Regulation Of Receptor Internalization Learning Or Memory Positive Regulation Of Gene Expression Positive Regulation Of Cell Death Wnt Signaling Pathway Negative Regulation Of Wnt Signaling Pathway Negative Regulation Of Ossification Negative Regulation Of Protein Binding Negative Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Mesodermal Cell Fate Specification Regulation Of Endodermal Cell Fate Specification Negative Regulation Of Apoptotic Process Positive Regulation Of JUN Kinase Activity Positive Regulation Of Wnt Signaling Pathway, Calcium Modulating Pathway Limb Development Negative Regulation Of Pathway-restricted SMAD Protein Phosphorylation Positive Regulation Of Heart Induction By Negative Regulation Of Canonical Wnt Signaling Pathway Negative Regulation Of Canonical Wnt Signaling Pathway Modulation Of Age-related Behavioral Decline Synapse Pruning Positive Regulation Of Neuron Death Negative Regulation Of Canonical Wnt Signaling Pathway Involved In Cardiac Muscle Cell Fate Commitment Positive Regulation Of Tau-protein Kinase Activity Regulation Of Dopaminergic Neuron Differentiation Negative Regulation Of Wnt-Frizzled-LRP5/6 Complex Assembly Positive Regulation Of Wnt Signaling Pathway, Planar Cell Polarity Pathway Negative Regulation Of Signaling Receptor Activity Negative Regulation Of Cardiac Muscle Cell Differentiation	Behavioral Fear Response Response To Hypoxia Proteolysis Cell Adhesion Positive Regulation Of Cell Population Proliferation Negative Regulation Of Extracellular Matrix Disassembly T Cell Costimulation Regulation Of Cell-cell Adhesion Mediated By Integrin Locomotory Exploration Behavior Psychomotor Behavior T Cell Activation Endothelial Cell Migration Viral Entry Into Host Cell Regulation Of Insulin Secretion Negative Chemotaxis Negative Regulation Of Neutrophil Chemotaxis
Pathways		TCF dependent signaling in response to WNT Negative regulation of TCF-dependent signaling by WNT ligand antagonists Signaling by LRP5 mutants	Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
Drugs			Atorvastatin Sitagliptin 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One 5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine (2s)-Pyrrolidin-2-Ylmethylamine 4-Iodo-L-phenylalanine Diisopropylphosphono Group 1-(1-phenylcyclopentyl)methylamine (S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide Vildagliptin PSN9301 AMG-222 Bisegliptin Alogliptin Saxagliptin (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE (2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine (3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine (7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine (2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE (2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE (2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE 4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide (2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine 7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile 4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE 1-biphenyl-2-ylmethanamine (1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile (2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE (4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE (3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE 1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE ABT-341 (2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE (3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE Gosogliptin N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide (3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE 6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM 7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE 2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE 4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE 2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE Linagliptin Dutogliptin
Diseases
GWAS		Blood protein levels ( 29875488) Bone properties (heel) ( 24430505) Chin dimples ( 27182965) Electrocardiogram morphology (amplitude at temporal datapoints) ( 32916098) Electrocardiographic traits ( 20062063) Fractures ( 30158200) Logical memory (delayed recall) in normal cognition ( 29274321) Metabolite levels ( 23823483) Monobrow ( 27182965) Periodontitis (Mean PAL) ( 24024966) QRS complex (12-leadsum) ( 27659466) QRS complex (Cornell) ( 27659466) QRS duration ( 27577874 21076409 27659466) Triglyceride levels x loop diuretics use interaction ( 31806883)	Asthma ( 32296059) Blood osmolality (transformed sodium) ( 28360221) Brain morphology (min-P) ( 32665545) Brain morphology (MOSTest) ( 32665545) Cognitive ability ( 29186694) Cognitive ability (MTAG) ( 29186694) Cortical surface area (MOSTest) ( 32665545) Cortical thickness (MOSTest) ( 32665545) Dentate gyrus molecular layer volume ( 30279459) General cognitive ability ( 29844566) Hippocampal tail volume ( 30279459) Hippocampal tail volume (corrected for total hippocampal volume) ( 30279459) Hippocampal volume ( 22504421) Intelligence (MTAG) ( 29326435) Multiple sclerosis ( 31604244) Reaction time ( 29844566) Regular attendance at a pub or social club ( 29970889) Rheumatoid arthritis ( 24782177) Schizophrenia ( 25056061 29483656) Smoking initiation (ever regular vs never regular) ( 30679032) Smoking status (ever vs never smokers) ( 30643258) Subcortical volume (min-P) ( 32665545) Subcortical volume (MOSTest) ( 32665545) Subiculum volume ( 30279459) Total hippocampal volume ( 30279459) Tourette syndrome ( 30818990)
Interacting Genes		8 interacting genes: CKAP4 DPP4 KREMEN1 KRTAP10-1 LRP5 LRP6 MDFI SMAD9	16 interacting genes: ADA CCL11 CCL22 CCL3L1 CCL5 CD4 CPAMD8 CXCL10 CXCL11 CXCL12 CXCL9 CXCR4 DKK1 FAP GRP PTPRC
Entrez ID		22943	1803
HPRD ID		05544	02187
Ensembl ID		ENSG00000107984	ENSG00000197635
Uniprot IDs		I1W660 O94907	P27487
PDB IDs		3S2K 3S8V 3SOQ 5FWW 5GJE	1J2E 1N1M 1NU6 1NU8 1PFQ 1R9M 1R9N 1RWQ 1TK3 1TKR 1U8E 1W1I 1WCY 1X70 2AJL 2BGN 2BGR 2BUB 2FJP 2G5P 2G5T 2G63 2HHA 2I03 2I78 2IIT 2IIV 2JID 2OAG 2OGZ 2OLE 2ONC 2OPH 2OQI 2OQV 2P8S 2QJR 2QKY 2QOE 2QT9 2QTB 2RGU 2RIP 3BJM 3C43 3C45 3CCB 3CCC 3D4L 3EIO 3F8S 3G0B 3G0C 3G0D 3G0G 3H0C 3HAB 3HAC 3KWF 3KWJ 3NOX 3O95 3O9V 3OC0 3OPM 3Q0T 3Q8W 3QBJ 3SWW 3SX4 3VJK 3VJL 3VJM 3W2T 3WQH 4A5S 4DSA 4DSZ 4DTC 4G1F 4J3J 4JH0 4KR0 4L72 4LKO 4N8D 4N8E 4PNZ 4PV7 4QZV 5I7U 5ISM 5J3J 5KBY 5T4B 5T4E 5T4F 5T4H 5Y7H 5Y7J 5Y7K 5ZID 6B1E 6B1O
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?